Evidence map›Paper›PMID 41340777›Full record

ArticleBone reports2025

Combination or sequential teriparatide for osteoporosis treatment in denosumab-users: real-world bone mineral density outcomes.

Shejil Kumar, Courtney Streeter, Michelle M McDonald, Roderick J Clifton-Bligh, Matti L Gild, Christian M Girgis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bone reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. A new age of osteoanabolic therapy? A real-world, two-centre study comparing effects of romosozumab, teriparatide, and antiresorptive therapies for osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shejil KumarDepartment of Endocrinology, Royal North Shore Hospital, Sydney, Australia.
Courtney StreeterFaculty of Medicine & Health, The University of Sydney, Sydney, Australia.
Michelle M McDonaldFaculty of Medicine & Health, The University of Sydney, Sydney, Australia.
Roderick J Clifton-BlighDepartment of Endocrinology, Royal North Shore Hospital, Sydney, Australia.
Matti L GildDepartment of Endocrinology, Royal North Shore Hospital, Sydney, Australia.
Christian M GirgisFaculty of Medicine & Health, The University of Sydney, Sydney, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The optimal osteoanabolic strategy in denosumab (Dmab)-users remains uncertain. In treatment-naïve patients, Dmab/teriparatide (TPTD) combinations result in dramatic bone mineral density (BMD) gains at the spine and hip. However, BMD outcomes with combination Dmab/TPTD have not been investigated in patients on

Indexed as

Bone mineral densityCombinationDenosumabOsteoporosisSequenceTeriparatide

Identifiers

PMID41340777
PMCPMC12669903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.